0001213900-26-045171
SEC filingRegencell Bioscience Holdings Limited disclosed Item 16 F(a)(1)(v) of Form 20-F regarding its engagement of HTL as auditor, with no prior consultations and Marcum Asia's agreement to the disclosures.
This Form 6-K fulfills Item 16 F(a)(1)(v) requirements of Form 20-F instructions by confirming no prior consultations with newly engaged auditor HTL on accounting, auditing, or reporting matters during specified fiscal years and interim period. The absence of such consultations or disagreements reduces regulatory risk associated with the auditor transition. Prior auditor Marcum Asia reviewed the disclosures and explicitly agreed with statements about their firm, providing SEC-required confirmation via Exhibit 16.1 dated April 17, 2026. This supports smooth changeover process following the company's engagement of HTL on April 16, 2026, excluding material weaknesses previously disclosed in the October 31, 2025 Form 20-F.